Suryoday Small Finance Bank reported a strong turnaround in fourth-quarter earnings with improved profitability and higher operating profit...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Bain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...

Lupin shares saw an uptick after Jefferies raised its target price and reiterated a “Buy” rating post-strong Q2 results. The US business hi...

Lupin plans a significant $250 million investment over five years to establish a new manufacturing facility in Coral Springs, Florida. This...

Lupin's margin guidance remains around 19.5-20.5%. The company attributes its success to the pivot to complex products, cost-led initiative...

Spiro, who had most recently served as president of Specialty Generics business at Mallinckrodt Pharmaceuticals and the president of US Inj...

The drug firm is banking on the introduction of complex generics and biosimilars in the US to maintain its top five position in the market.

His past experiences include Business Unit Head for Reproductive Health at Ferring Pharmaceuticals, Inc and Senior Vice President of Sales ...

Lupin had entered into an arrangement to acquire the company earlier this year.

The global investment bank is of the view that in-licensing deals are likely to drive the Indian business.

A day after announcing its biggest acquisition deal of $880 million, Lupin today said it will buy Germany-based Temmler Pharma's specialty ...

Lupin's revenue grew 5% yearon-year to Rs 3,144.9 crore during the December 2014 quarter, much lower than the analysts' expectation of 12-1...

Lupin Pharma’s underperformance in the domestic market may rein in investors’ bullish stance on the share — a hitherto darling of the India...

Lupin had posted net profit of Rs 290.5 crore in July- September quarter of the previous fiscal, 2012-13.

As per the IMS data, the total sales for branded and generic sales for the product stood at $ 361 million for the year ended December 2012.

For a fairly consistent performer in terms of top line growth in the pharma industry, drug maker Lupin’s show in the quarter to December wa...